● Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Condition: Ovarian Cancer · Sponsor: M.D. Anderson Cancer Center

PhasePhase 2

Planned participants20

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.

This description comes directly from the study's public registry record.

Talk to the study team

Amir Jazaeri, MD · (713) 745-1613 · aajazaeri@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (2)

Memorial Sloan Kettering Cancer Center	New York, New York, United States	Active Not Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06083844